Seegene Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Seegene wird ein jährliches Gewinn- und Umsatzwachstum von 75.5% bzw. 13.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 75.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 4% betragen.

Wichtige Informationen

28.5%

Wachstumsrate der Gewinne

24.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	64.4%
Wachstumsrate der Einnahmen	13.9%
Zukünftige Eigenkapitalrendite	4.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

Gewinn- und Umsatzwachstumsprognosen

KOSDAQ:A096530 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	545,000	51,000	29,000	49,000	1
12/31/2025	459,250	37,750	24,000	44,000	2
12/31/2024	400,000	32,900	49,000	79,000	1
6/30/2024	382,484	23,128	51,929	84,168	N/A
3/31/2024	367,272	-3,461	43,736	74,663	N/A
12/31/2023	367,375	669	63,053	94,932	N/A
9/30/2023	389,688	-2,578	60,269	96,806	N/A
6/30/2023	448,646	-8,971	38,577	80,689	N/A
3/31/2023	492,159	18,719	34,182	92,771	N/A
12/31/2022	853,561	182,139	246,557	319,009	N/A
9/30/2022	1,140,776	343,230	323,190	401,561	N/A
6/30/2022	1,295,241	447,057	496,227	579,900	N/A
3/31/2022	1,470,535	537,404	501,890	574,273	N/A
12/31/2021	1,370,833	536,559	267,913	334,024	N/A
9/30/2021	1,402,531	559,365	307,852	377,100	N/A
6/30/2021	1,424,097	618,128	153,723	331,480	N/A
3/31/2021	1,395,194	633,289	218,235	393,526	N/A
12/31/2020	1,125,216	502,281	207,900	383,157	N/A
9/30/2020	717,254	321,437	79,846	234,884	N/A
6/30/2020	421,777	175,809	73,584	103,313	N/A
3/31/2020	176,245	55,324	10,467	31,529	N/A
12/31/2019	121,953	26,672	22,354	27,141	N/A
9/30/2019	118,445	26,676	18,474	22,290	N/A
6/30/2019	110,402	23,176	18,418	21,008	N/A
3/31/2019	105,861	14,304	13,156	15,670	N/A
12/31/2018	102,265	10,098	10,045	14,010	N/A
9/30/2018	97,975	5,951	11,019	17,831	N/A
6/30/2018	94,684	4,972	7,785	9,870	N/A
3/31/2018	91,979	4,684	N/A	8,555	N/A
12/31/2017	88,920	3,693	N/A	10,115	N/A
9/30/2017	83,092	6,568	N/A	9,699	N/A
6/30/2017	80,817	4,644	N/A	19,233	N/A
3/31/2017	77,285	5,672	N/A	22,227	N/A
12/31/2016	73,694	7,123	N/A	16,557	N/A
9/30/2016	70,519	2,827	N/A	6,916	N/A
6/30/2016	67,973	6,367	N/A	705	N/A
3/31/2016	65,903	6,289	N/A	-607	N/A
12/31/2015	65,137	6,774	N/A	-3,122	N/A
9/30/2015	63,834	9,204	N/A	6,752	N/A
6/30/2015	63,538	8,620	N/A	9,213	N/A
3/31/2015	63,807	8,412	N/A	12,028	N/A
12/31/2014	64,411	9,141	N/A	6,777	N/A
9/30/2014	65,029	8,021	N/A	4,132	N/A
6/30/2014	65,141	8,067	N/A	1,292	N/A
3/31/2014	62,595	9,414	N/A	-5,939	N/A
12/31/2013	58,993	9,573	N/A	-2,893	N/A
9/30/2013	58,798	10,338	N/A	-3,491	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A096530Das prognostizierte Gewinnwachstum (28.5% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: A096530Die Erträge des Unternehmens (28.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (28.8% pro Jahr).

Hohe Wachstumserträge: A096530Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: A096530Die Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt KR (10.2% pro Jahr).

Hohe Wachstumseinnahmen: A096530Die Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A096530Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (4%).

Seegene Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.8% to ₩25,000

Consensus EPS estimates fall from profit to ₩18.00 loss

Consensus revenue estimates fall by 21%

Price target decreased to ₩38,667

Consensus revenue estimates fall by 24%

Price target decreased to ₩71,500

Recent updates

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC

Price target decreased to ₩89,000

Consensus EPS estimates increase to ₩9,305

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021

Investor sentiment improved over the past week

Price target decreased to ₩116,750

Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩19,324 (vs ₩1,026 in FY 2019)